XNYS
COR
Market cap62bUSD
Oct 08, Last price
321.35USD
1D
1.29%
1Q
5.90%
Jan 2017
310.99%
Name
Amerisourcebergen Corp
Chart & performance
P/E
40.23
P/S
0.19
EPS
7.99
Div yield, %
0.70%
Shrs. gr., 5y
-0.95%
Rev. gr., 5y
11.09%
Revenues
321.33b
+9.31%
Net income
1.55b
+2.99%
CFO
3.88b
+11.20%
Dividend
Aug 14, 20260.6 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AmerisourceBergen Corporation (ABC) operates as a prominent global distributor and procurer of pharmaceutical products. Its core business is structured around two main segments. The Pharmaceutical Distribution division is responsible for the extensive supply of both brand-name and generic medicines, alongside over-the-counter health items, and equipment for home healthcare. This segment extends its services to a wide array of healthcare entities, including acute care hospitals, integrated health systems, independent and chain retail pharmacies, mail-order drug providers, medical clinics, and facilities offering long-term care or alternative site pharmacy services. Beyond product distribution, it offers comprehensive pharmacy management and staffing solutions, consulting expertise, and specialized supply chain software tailored for both retail and institutional healthcare settings. Furthermore, ABC provides bespoke packaging services. This division also manages the distribution of vital plasma and blood products, various injectable pharmaceuticals, vaccines, and other specialty medications. It furnishes support services primarily to physicians specializing in areas like oncology, as well as to hospitals and dialysis centers, while also delivering critical data analytics, outcomes research, and supplementary services to biotechnology and pharmaceutical manufacturers. The Other segment encompasses a range of integrated services for manufacturers, spanning clinical trial assistance, post-approval support, and commercialization strategies for new products. It also manages specialized transportation and logistics crucial for the biopharmaceutical sector. Additionally, this segment supplies pharmaceuticals, vaccines, parasiticides, diagnostic tools, and micro feed ingredients to both companion animal and production animal markets. It further aids manufacturers by providing sales force services aimed at generating demand. AmerisourceBergen Corporation was established in 2001 and maintains its headquarters in Conshohocken, Pennsylvania.
Related entities
Subsidiaries (4)
AB FINCO LTD
BEACHCOURSE LIMITED
OTC DIRECT LIMITED
ALLIANCE HEALTHCARE S.R.O
Key people
D. Mark Durcan
Non-Executive Independent Chairman of the Board · since 2025
Robert Mauch
President, Chief Executive Officer, Director · since 2024
Chief Human Resources Officer, Executive Vice President · since 2019
Elizabeth Campbell
Executive Vice President, Chief Legal Officer · since 2021
Chief Financial Officer, Executive Vice President · since 2018
Francois Mandeville
Executive Vice President - Strategy and M&A · since 2024
Pawan Verma
Executive Vice President, Chief Data and Information Officer · since 2024
Executive Chairman of the Board · since 2024
Director · since 2015
Independent Director · since 2023
Franklin Clyburn
Independent Director · since 2024
Independent Director · since 2026
Lon Greenberg
Independent Director · since 2013
Independent Director · since 2022
Redonda Miller
Independent Director · since 2023
Independent Director · since 2020
Independent Director · since 2025
Independent Director · since 2023
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
1 West First Avenue
Conshohocken, PA 19428
US
Conshohocken, PA 19428
US
Previous name
Amerisource-Bergen Corporation
Previous name
AMERISOURCEBERGEN CORPORATION
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||